Edison issues review -The Biotech Growth Trust

RNS Number : 2725J

Biotech Growth Trust PLC (The)

16 December 2015

 

London, UK, 16 December 2015

Edison issues research review on The Biotech Growth Trust

The Biotech Growth Trust (BIOG) invests worldwide in the innovative area of biotechnology, with the aim of achieving capital growth. Biotech has been one of the strongest-performing market sectors in recent years, but controversy over drug pricing in the US caused a sell-off in September, denting returns over shorter periods. BIOG's managers argue that truly innovative and effective new treatments will continue to have strong pricing power. The trust's investment approach is catalyst-driven, with specialist managers and analysts assessing the likelihood of clinical success and positioning the portfolio accordingly. This strategy has worked well in the long term but a small number of company-specific events has affected recent performance, and BIOG's discount is currently towards the wider end of historical ranges, with potential for rerating.

At 14 December BIOG's shares traded at a 6.3% discount to NAV. This is higher than the one-, three- and five-year averages (4.6%, 3.8% and 4.4% respectively), and compares with a 12-month high of 10.9% seen in early May. With a spell of recent underperformance versus the NASDAQ Biotech index having dented BIOG's track record, there is scope for a rerating in the shares should the previous trend of above-benchmark returns be re-established.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website. www.edisoninvestmentresearch.com

About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring that a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn	www.linkedin.com/company/edison-investment-research
Twitter	www.twitter.com/Edison_Inv_Res
YouTube	www.youtube.com/edisonitv
Google+	https://plus.google.com/105425025202328783163/posts

 

END

 

 

NRALQLFFELFBFBB